<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574157</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-002-11F</org_study_id>
    <nct_id>NCT01574157</nct_id>
  </id_info>
  <brief_title>Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.</brief_title>
  <official_title>Investigations of the Optimum Serum Bicarbonate Level in Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if treatment with sodium bicarbonate will lower urine
      levels of proteins that are indicators of kidney damage in people with diabetes who also have
      chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic chronic kidney disease (CKD) is a common problem in Veterans and progresses to
      end-stage renal disease in many people. It is important to identify treatment strategies that
      will help prevent the progression of CKD to overt kidney failure. The purpose of this study
      is to see if sodium bicarbonate reduces urinary markers of kidney damage in Veterans with
      diabetic CKD and normal serum bicarbonate levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2012</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1)</measure>
    <time_frame>The mean of the 3-month and 6-month urinary TGF-b1 measurement will be compared to the baseline value between the groups.</time_frame>
    <description>Urinary TGF-b1 is considered a marker of renal fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Levels of Kidney Injury Molecule-1 (KIM-1)</measure>
    <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
    <description>KIM-1 is a marker of of kidney injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Levels of Neutrophil Gelatinase-associated Lipocalin (NGAL)</measure>
    <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
    <description>NGAL is a marker of kidney injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Levels of Fibronectin</measure>
    <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
    <description>Fibronectin is a marker of kidney injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Albumin Levels</measure>
    <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
    <description>Urinary albumin is a marker of kidney damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration (eGFR)</measure>
    <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
    <description>eGFR is a measure of kidney function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.</description>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veteran

          -  Age older than 18 years

          -  Diabetes mellitus

          -  Serum bicarbonate 22 - 28 mmol/L on the most recent measurement within the past six
             months

          -  Stage 2, 3, or 4 CKD (defined as estimated glomerular filtration rate (eGFR) 15 - 89
             ml/min/1.73m2 using the CKD-Epidemiology equation)

          -  Urinary albumin:creatinine ratio &gt; 30 mg/gm on the most recent sample within the past
             12 months.

        Exclusion Criteria:

          -  Lean body weight &gt; 100 kg

          -  Use of oral medications typically prescribed to raise low serum bicarbonate levels
             (i.e. sodium bicarbonate, sodium citrate, potassium citrate).

          -  Serum potassium &lt; 3.5 meq/L at enrollment visit

          -  Use of 5 or more antihypertensive agents, regardless of the indications of each agent

          -  Systolic blood pressure &gt; 140 mmHg or diastolic blood pressure &gt; 90 mmHg at the
             enrollment or baseline visit

          -  Diagnosis of congestive heart failure with current, active Class III or IV New York
             Heart Association symptoms.

          -  Significant fluid overload such that it is unsafe in the opinion of the PI for the
             patient to participate in the trial

          -  chronic gastrointestinal disorder or any other factors judged to be likely to limit
             adherence to interventions (i.e. alcoholism, a history of missing clinic visits)

          -  Chronic immunosuppressive therapy for transplanted organs or other indications

          -  Individuals who are currently a member of a vulnerable population (I.e. incarcerated,
             pregnant).

             11.Currently participating in another interventional research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kalani L Raphael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Salt Lake City Health Care System, Salt Lake City, UT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <results_first_submitted>June 26, 2019</results_first_submitted>
  <results_first_submitted_qc>August 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT01574157/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from VA Salt Lake City Healthcare System from November 2012 to October 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sodium Bicarbonate</title>
          <description>Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Month 3</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sodium Bicarbonate</title>
          <description>Sodium bicarbonate: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="8"/>
                    <measurement group_id="B2" value="73" spread="8"/>
                    <measurement group_id="B3" value="72" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate</title>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="20"/>
                    <measurement group_id="B2" value="52" spread="16"/>
                    <measurement group_id="B3" value="51" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129" spread="12"/>
                    <measurement group_id="B2" value="127" spread="11"/>
                    <measurement group_id="B3" value="128" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of angiotensin converting enzyme-inhibitor (ACE-I) or angiotensin receptor blocker (ARB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100" spread="18"/>
                    <measurement group_id="B2" value="101" spread="22"/>
                    <measurement group_id="B3" value="101" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lean body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="8"/>
                    <measurement group_id="B2" value="68" spread="9"/>
                    <measurement group_id="B3" value="68" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive heart failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum total carbon dioxide (CO2)</title>
          <units>meq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="3"/>
                    <measurement group_id="B2" value="24" spread="2"/>
                    <measurement group_id="B3" value="24" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum potassium</title>
          <units>meq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="0.4"/>
                    <measurement group_id="B2" value="4.3" spread="0.4"/>
                    <measurement group_id="B3" value="4.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" spread="1.0"/>
                    <measurement group_id="B2" value="7.6" spread="1.3"/>
                    <measurement group_id="B3" value="7.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary albumin/creatinine</title>
          <units>mg/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121" lower_limit="84" upper_limit="412"/>
                    <measurement group_id="B2" value="131" lower_limit="46" upper_limit="324"/>
                    <measurement group_id="B3" value="121" lower_limit="58" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary pH</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="0.4"/>
                    <measurement group_id="B2" value="5.4" spread="0.4"/>
                    <measurement group_id="B3" value="5.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary ammonium</title>
          <units>meq/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="18"/>
                    <measurement group_id="B2" value="33" spread="21"/>
                    <measurement group_id="B3" value="34" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary titratable acids</title>
          <units>meq/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="14"/>
                    <measurement group_id="B2" value="31" spread="16"/>
                    <measurement group_id="B3" value="32" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary transforming growth factor-B1/creatinine</title>
          <units>ng/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122" lower_limit="79" upper_limit="186"/>
                    <measurement group_id="B2" value="103" lower_limit="68" upper_limit="147"/>
                    <measurement group_id="B3" value="112" lower_limit="74" upper_limit="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary kidney injury molecule-1/creatinine</title>
          <units>ng/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.91" lower_limit="0.57" upper_limit="1.87"/>
                    <measurement group_id="B2" value="0.88" lower_limit="0.59" upper_limit="1.89"/>
                    <measurement group_id="B3" value="0.89" lower_limit="0.58" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary fibronectin/creatinine</title>
          <units>ng/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107" lower_limit="75" upper_limit="194"/>
                    <measurement group_id="B2" value="97" lower_limit="65" upper_limit="147"/>
                    <measurement group_id="B3" value="102" lower_limit="74" upper_limit="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary neutrophil gelatinase-associated lipocalin/creatinine</title>
          <units>ng/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" lower_limit="7.0" upper_limit="23.6"/>
                    <measurement group_id="B2" value="11.9" lower_limit="6.3" upper_limit="24.0"/>
                    <measurement group_id="B3" value="11.1" lower_limit="6.5" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1)</title>
        <description>Urinary TGF-b1 is considered a marker of renal fibrosis</description>
        <time_frame>The mean of the 3-month and 6-month urinary TGF-b1 measurement will be compared to the baseline value between the groups.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
Sodium bicarbonate: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
Placebo: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1)</title>
          <description>Urinary TGF-b1 is considered a marker of renal fibrosis</description>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="-9.6" upper_limit="28.0"/>
                    <measurement group_id="O2" value="-4.4" lower_limit="-19.4" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis compared the mean change from baseline in the sodium bicarbonate group to the mean change from baseline in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>40.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Levels of Kidney Injury Molecule-1 (KIM-1)</title>
        <description>KIM-1 is a marker of of kidney injury.</description>
        <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Levels of Kidney Injury Molecule-1 (KIM-1)</title>
          <description>KIM-1 is a marker of of kidney injury.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" lower_limit="-33.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-24.9" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main analytic strategy for this secondary outcome was a comparison of the mean change from baseline in the sodium bicarbonate group to the mean change from baseline in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.2</ci_lower_limit>
            <ci_upper_limit>30.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Levels of Neutrophil Gelatinase-associated Lipocalin (NGAL)</title>
        <description>NGAL is a marker of kidney injury</description>
        <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
Sodium bicarbonate: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
Placebo: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Levels of Neutrophil Gelatinase-associated Lipocalin (NGAL)</title>
          <description>NGAL is a marker of kidney injury</description>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.5" lower_limit="-48.7" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="5.9" lower_limit="-23.9" upper_limit="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main analytic strategy for this secondary outcome was a comparison of the mean change from baseline in the sodium bicarbonate group to the mean change from baseline in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-32.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.3</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Levels of Fibronectin</title>
        <description>Fibronectin is a marker of kidney injury.</description>
        <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Levels of Fibronectin</title>
          <description>Fibronectin is a marker of kidney injury.</description>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="-9.4" upper_limit="30.7"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-15.8" upper_limit="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main analytic strategy for this secondary outcome was a comparison of the mean change from baseline in the sodium bicarbonate group to the mean change from baseline in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>36.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Albumin Levels</title>
        <description>Urinary albumin is a marker of kidney damage</description>
        <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>Sodium bicarbonate: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Albumin Levels</title>
          <description>Urinary albumin is a marker of kidney damage</description>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="-3.1" upper_limit="51.3"/>
                    <measurement group_id="O2" value="11.9" lower_limit="-10.5" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main analytic strategy for this secondary outcome was a comparison of the mean change from baseline in the sodium bicarbonate group to the mean change from baseline in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.6</ci_lower_limit>
            <ci_upper_limit>35.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Glomerular Filtration (eGFR)</title>
        <description>eGFR is a measure of kidney function</description>
        <time_frame>The mean of the 3-month and 6-month measurements will be compared to the baseline values between the groups.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sodium Bicarbonate</title>
            <description>Sodium bicarbonate: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated Glomerular Filtration (eGFR)</title>
          <description>eGFR is a measure of kidney function</description>
          <units>ml/min per 1.73m2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="-0.47" upper_limit="4.40"/>
                    <measurement group_id="O2" value="-1.41" lower_limit="-3.80" upper_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main analytic strategy for this secondary outcome was a comparison of the mean change from baseline in the sodium bicarbonate group to the mean change from baseline in the placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>6.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during each participant's 6-month follow-up period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sodium Bicarbonate</title>
          <description>Sodium bicarbonate: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Change in urinary levels of Bb and membrane attack complex (MAC) were initial secondary outcomes. However, we had difficulty measuring these. Many subjects could not complete the physical activity assessment, which was an initial secondary outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kalani Raphael, Principal Investigator</name_or_title>
      <organization>VA Salt Lake City Healthcare System</organization>
      <phone>801-582-1565 ext 1794</phone>
      <email>kalani.raphael@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

